Name: Neurologic Cancers: Selections from "The World Market for Neurotherapeutic Drugs"
SKU: KLI847932
Availability: InStock

Description

In the summer of 2002, Kalorama Information released a major study on non-psychiatric neurotherapeutic drug markets. At almost 500 pages, the resulting report covered a broad range of neurological agents comprehensively and in depth; however, the breadth and authority of the results proved to be more information than some marketers needed. Smaller biopharmaceutical concerns—some of the real drivers of this market—are more focused on individual neurological disorders such as multiple sclerosis, Alzheimer’s disease, or neurological cancers, rather than the broad therapeutic category as a whole.

Therefore, Kalorama is now offering selections from the neurotherapeutics study, covering each of these topics in turn, while at the same time providing selected overall findings in other disease areas to allow for comparison and context. The selections provide the study’s full results in the specific area and the general context and strategic implications from the full study, all at a fraction of the cost.

Among the selections, you’ll find:

I. Executive Summary (15 pages) —Included in this selection is the complete executive summary from the full neurotherapeutics report, providing you with an overview of the entire neurotherapeutics market and top-level numbers on such neurological diseases as peripheral neuropathy, Parkinson’s disease, and Alzheimer’s disease, among others for the top seven world markets. The executive summary outlines the context of the entire neurology market and how oncology therapeutics fit in.

II. Introduction (31 pages) —Selection includes the overview of neurologic cancer, including prevalence estimates.

III. Treatment (11 pages) —This selection reviews current treatment protocols and the agents used in various forms of brain and spinal tumors.

IV. Progress and Promise in Therapeutic Development (62 pages) —Because progress on other neurotherapeutic fronts can have significant impact on oncology, information about all of the developments in neurogenomics and neural implants that the full study covered are included in this selection. Information specific to cancer includes Table 4-4: Active Clinical Trials Involving Neurologic Cancers.

V. World Market Analysis (28 pages, including 10 tables and 4 figures) —Selection provides complete projections and growth rates for neurologic cancer treatment potential in each of the top world markets. Growth rates for other major neurological diseases are included, along with total world numbers for comparison.

VI. Company Profiles (50 pages) —Profiles of the following companies are included:

Boston Life Sciences, Inc.
Cephalon, Inc.
Curis, Inc.
D-Pharm Ltd.
Guilford Pharmaceuticals Inc.
NeoTherapeutics, Inc.
Neurobiological Technologies, Inc.
Neurocrine BioSciences, Inc.
Titan Pharmaceuticals, Inc.

VII. Conclusions and Strategic Implications (9 pages) —This selection represents all of the analyst’s conclusions from the neurotherapeutics study as a whole, spelling out seven main conclusions and what they mean for developers and marketers of neurotherapeutic agents.

VIII. Glossary (8 pages)

IX. Company Directory (8 pages)

Executive Summary

Background
Scope and Methodology
Size and Growth of Market
Market Trends

Overview of Neurologic Diseases and Disorders

Background

- - History
  - Neurologic Examination
  - Diagnostic Procedures

Pathophysiology

- - Peripheral Nerve and Skeletal Muscle Diseases and Disorders
  - Central Nervous System Diseases and Disorders

Key Neurologic Diseases and Disorders

- Brain and Spinal Tumors
- Neurofibromatosis

Treatment of Neurologic Diseases and Disorders

Cancer

Progress and Promise in Therapeutics Development

Genetics and Neurogenomics

Neural Implant Technologies

Miscellaneous Advances

- - Vascular Endothelial Growth Factor (VEGF)
  - Minocycline
  - Stroke and Apoptosis

Clinical Trial Activity

World Market Analysis

Background

The Markets by Geography

- - The United States
  - France
  - Germany
  - Italy
  - Spain
  - United Kingdom
  - Japan

The Market by Applications

- Brain/Neurologic Cancers

Company Profiles

Boston Life Sciences, Inc.
Cephalon, Inc.
Curis, Inc.
D-Pharm Ltd.
Guilford Pharmaceuticals Inc.
NeoTherapeutics, Inc.
Neurobiological Technologies, Inc.
Neurocrine BioSciences, Inc.
Titan Pharmaceuticals, Inc.

Conclusions and Strategic Implications

First Conclusion
Second Conclusion
Third Conclusion
Fourth Conclusion
Fifth Conclusion
Sixth Conclusion
Seventh Conclusion

Glossary

Company Directory

List of Exhibits

Table 1-1: Estimated Market Sizes for the Top Five Applications Segments for Neurotherapeutics in the Major World Healthcare Markets, 2001-2009
Table 1-2: Estimated Market Sizes for the Geographic Segments for Neurotherapeutics in the Major World Healthcare Markets, 2001-2009
Table 2-1: Neurologic Diseases and Disorders as Classified by the United States National Institute of Neurological Disorders and Stroke 2002
Table 2-2: Classification of Diseases and Disorders of Peripheral Nerve and Skeletal Muscle
Table 2-3: Classification of Diseases and Disorders of the Central Nervous System
Table 3-7: Therapies for Key Neurologic Cancers
Table 4-4: Active Clinical Trials Involving Neurologic Cancers
Table 5-1: The Potential for Neurotherapeutics in the Seven Major World Healthcare Markets, 2001-2010
Table 5-2: The Potential for Neurotherapeutics in the United States by Application, 2001-2010
Table 5-3: The Potential for Neurotherapeutics in France by Application, 2001-2010
Table 5-4: The Potential for Neurotherapeutics in Germany by Application, 2001-2010
Table 5-5: The Potential for Neurotherapeutics in Italy by Application, 2001-2010
Table 5-6: The Potential for Neurotherapeutics in Spain by Application, 2001-2010
Table 5-7: The Potential for Neurotherapeutics in the United Kingdom by Application, 2001-2010
Table 5-8: The Potential for Neurotherapeutics in Japan by Application, 2001-2010
Table 5-9: The Potential for Neurotherapeutics in the Major World Healthcare Markets by Application 2001-2010
Table 5-12: The Potential for Brain and Neurologic Cancer Therapeutics in the Major World Healthcare Markets 2001-2010
Table 5-19: The Potential for Spinal Cord Injury Therapeutics in the Major World Healthcare Markets 2001-2010
Table 5-20: The Potential for Stroke Therapeutics in the Major World Healthcare Markets 2001-2010
Table 5-21: The Potential for Traumatic Brain Injury Therapeutics in the Major World Healthcare Markets 2001-2010
Figure 1-1: Incidence of Major Neurologic Diseases in the Major World Healthcare Markets, 2001-2010
Figure 1-2: The Total Market for Neurotherapeutics in the Major World Healthcare Markets, 2001-2010
Figure 1-3: Growth Rates in the World’s Seven Major Neurotherapeutics Markets by Application, 2001-2009
Figure 1-4: Growth Rates in the World’s Seven Major Neurotherapeutics Markets by Geographic Region, 2001-2009
Figure 1-5: Composition of the Markets for Neurotherapeutics by Applications Segment, 2002 and 2010
Figure 1-6: Composition of the Markets for Neurotherapeutics by Geographic Segment, 2002 and 2010
Figure 2-1: Structure of the Normal Motor Neuron
Figure 4-1: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 1-4
Figure 4-2: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 5-8
Figure 4-3: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 9-12:
Figure 4-4: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 13-16
Figure 4-5: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 17-20
Figure 4-6: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 21, 22, X, and Y
Figure 5-1: Growth Rates in Neurotherapeutics Potential for the Seven Major World Healthcare Markets, 2001-2010
Figure 5-2: Distribution of the Estimated Market Potential for Neurotherapeutics in the Seven Major World Healthcare Markets, 2002
Figure 5-3: Growth Rates in Neurotherapeutics Market Opportunities 2001-2010
Figure 5-4: Distribution of the Estimated Market Potential for Neurotherapeutics in the Seven Major World Healthcare Markets by Application, 2002